Longitudinal survey of ischaemic heart disease in randomly selected sample of older population.

Kitchin, A. H.; Milne, John

doi:10.1136/hrt.39.8.889

Cited by 62 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study in the United States, however, reported prevalences of 0.3% in people aged 65-69, 1.5% in those aged 70-79, and 3% in those aged over 80 30. The higher mortality from cerebrovascular and cardiovascular disease in the United Kingdom would suggest that atrial fibrillation may be more prevalent here, but British studies of prevalence have involved small numbers of elderly patients from unrepresentative populations 33 34 35 36 37 38. Best estimates are therefore based on the Australian and North American studies.…”

Section: Prevalence Of Atrial Fibrillationmentioning

confidence: 86%

How To Do It: Service provision and use of anticoagulants in atrial fibrillation

Sudlow

Rodgers

Kenny

et al. 1995

BMJ

View full text Add to dashboard Cite

Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.

show abstract

Section: Prevalence Of Atrial Fibrillationmentioning

confidence: 86%

How To Do It: Service provision and use of anticoagulants in atrial fibrillation

Sudlow

Rodgers

Kenny

et al. 1995

BMJ

View full text Add to dashboard Cite

show abstract

“…11 In the Framingham study in subjects aged 55 to 94 years at baseline the biennial incidence of AF increased with age, ranging from 6.2 and 3.8 cases per 1000 person-examinations in men and women, respectively, aged 55 to 64 years, to 75.9 and 62.8 cases per 1000 person-examinations in men and women aged 85 to 94 years. 3 In the Framingham study arterial hypertension (odds ratio 1.5 in men and 1.4 in women) and diabetes mellitus (odds ratio 1.4 in men and 1.6 in women) emerged as significant independent predictors of AF.…”

Section: Vagaonescu Et Al Atrial Fibrillation In the Shep Studymentioning

confidence: 99%

Atrial Fibrillation and Isolated Systolic Hypertension

Vagaonescu¹,

Wilson²,

Kostis³

2008

Hypertension

View full text Add to dashboard Cite

Abstract-We performed a post hoc analysis of the Systolic Hypertension in the Elderly Program database to assess the incidence of atrial fibrillation in the elderly hypertensive population, its influence on cardiovascular events, and whether antihypertensive treatment can prevent its onset. The Systolic Hypertension in the Elderly Program was a double-blind placebo-controlled trial in 4736 subjects with isolated systolic hypertension aged Ն60 years. Atrial fibrillation was an exclusion criterion from the trial. Participants were randomly assigned to stepped care treatment with chlorthalidone and atenolol (nϭ2365) or placebo (nϭ2371). The occurrence of atrial fibrillation and cardiovascular events over 4.7 years as well as the determination of cause of death at 4.7 and 14.3 years were followed. Ninety-eight subjects (2.06%) developed atrial fibrillation over 4.7 years mean follow-up, without significant difference between treated and placebo groups. Atrial fibrillation increased the risk for: total cardiovascular events (RR Key Words: hypertension Ⅲ elderly Ⅲ atrial fibrillation Ⅲ chlorthalidone Ⅲ atenolol Ⅲ incidence Ⅲ death A trial fibrillation (AF) represents a major health problem, affecting more than 2 million patients in the United States. 1 The prevalence of AF increases with age and it is estimated to be around 5% above age 70. 2 In the Framingham study the incidence of AF in the general population approximately doubled for every 10-year increment in age beyond 50 years (approximately 10% in persons who reach age 80 3,4 ), and it was reported as high as 19.2 per 1000 person-years among adults above age 65 in the Cardiovascular Health Study. 5 Arterial hypertension is an independent risk factor for developing AF 3 and for an increased risk of stroke in patients with AF. 6 However, no study addressed specifically the incidence of AF, the relationship of AF on cardiovascular events, and the effect of antihypertensive treatment versus placebo on the incidence of AF in a well-characterized hypertensive population. To answer these questions we performed a posthoc analysis of the Systolic Hypertension in the Elderly Program (SHEP) database. Methods Participants and Study DesignSHEP was a double-blind, randomized, placebo-controlled trial design to test whether long-term administration of antihypertensive treatment to older persons with isolated systolic hypertension (SBP Ͼ160 mm Hg and DBP Ͻ90 mm Hg) reduces the combined incidence of fatal and nonfatal stroke during a 5-year follow-up. A cohort of 4736 men and women aged Ն60 years with hypertension as defined was followed up for an average of 4.7 years. Patients were randomized in a double-blind manner to a once-daily dose of either active drug treatment or matching placebo. The objective of the stepped care treatment program was to use the minimal amount of medication to maintain SBP at or below the goal (decrease in baseline SBP of at least 20 mm Hg and a SBP of less than 160 mm Hg). The first treatment step was chlorthalidone 12.5 mg/d (or matching placebo), ...

show abstract

“…The criteria for inclusion were as follows: (1) the trials were prospective and the findings were published; (2) …”

mentioning

confidence: 99%

Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide

Zarembski¹

1995

Archives of Internal Medicine

View full text Add to dashboard Cite

Longitudinal survey of ischaemic heart disease in randomly selected sample of older population.

Cited by 62 publications

References 10 publications

How To Do It: Service provision and use of anticoagulants in atrial fibrillation

How To Do It: Service provision and use of anticoagulants in atrial fibrillation

Atrial Fibrillation and Isolated Systolic Hypertension

Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide

Contact Info

Product

Resources

About